Summary
I think it shows two important things: 1) Teva admit that they are not in the best position to manufacture 2) That Teva remove a potential manufacturing competitor from the market
Analysis
In the big picture it means that Teva are following up their own investments in the sector by securing future products. Lonza are a quality partner, along with Teva's strength in patent development, its a strong partnership and one that Sandoz and others would be concerned about, given that they are investing in their own manufacturing. If Teva can't crack it by themselves, do the other believe they will be more successful??
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
